Disc Medicine surges on late-stage trial win for lead asset developed with Roche
The stock surged after Disc Medicine's key asset, co-developed with Roche, received approval in late-stage clinical trials.
The current price of 56.84 is close to the May 20 low support level of 55.00, the RSI is in an oversold state at 25.6, and the non-aligned moving averages and low trading volume suggest the possibility of a rebound. Therefore, purchasing near the support level is recommended.
I will take profit if the price reaches the resistance level of 69.84, and I will cut losses if the price falls to the support level of 55.00 (based on REPORTING calculations).
RSI (14) = 25.6 (oversold), moving averages in non-bullish alignment, volume = 0.87x of 20-day average (subdued), 7-day volatility = -7.1% (decline)
None
Compared to the predicted return of 3.5%, it recorded an excess return of 38.9% and was rated OVERHIT. The decision to buy based on news and proximity to the support line was correct, but the upward potential was significantly underestimated. Failing to fully recognize the possibility of a rise up to the resistance level of 69.84 was the main reason for the discrepancy.
In the next trade, when positive catalysts arise, the target resistance level can be set more aggressively, and the initial position can be expanded taking into account the oversold indicators and low trading volume. In addition, risks will be minimized by continuously monitoring SEC filings and thematic momentum.